Fig 1.
Simplified schematic of model.
This diagram depicts a simplified representation of the decision analysis model. The square indicates a decision node and the circles indicate probability nodes. Three different diagnostic and treatment strategies were considered over a two-year period in the decision analysis model: (1) AFB smear with WHO standard first line therapy for all people diagnosed with TB (2 months isoniazid, rifampin, pyrazinamide, ethambutol, followed by 4 months isoniazid, rifampin (2HRZE/4HR)); (2) Xpert MTB/RIF with standardized WHO recommended MDR-TB therapy for those with detected MDR-TB, and 2HRZE/4HR for the remainder; (3) LPA with a daily regimen of 6 months of rifampin, ethambutol, and pyrazinamide with or without isoniazid (6(H)REZ) for detected INHR-TB, standardized WHO recommended MDR-TB therapy for those with detected MDR-TB, and 2HRZE/4HR for the remainder. TB (tuberculosis); INHR (isoniazid resistant); MDR (multi-drug resistant); LPA (Line Probe Assay).
Table 1.
Summary of model inputs.
Table 2.
Diagnostic and treatment strategies.
Table 3.
Prevalence of MDR-TB in population after initial attempt at diagnosis and treatment, per 100 000 individuals with TB.
Table 4.
Total acquired MDR-TB in those with detected TB after initial attempt at diagnosis and treatment, per 100 000 individuals with TB.
Table 5.
Total death in population after initial attempt at diagnosis and treatment, per 100 000 individuals with TB.
Fig 2.
Total proportion of patients with MDR-TB after initial attempt at diagnosis and treatment, based on varying population INHR-TB prevalence.
Fig 3.
Proportion of patients with acquired MDR-TB after initial attempt at diagnosis and treatment, based on varying population INHR-TB prevalence.
Fig 4.
Relationship between drug resistance prevalence and diagnostic test to minimize total MDR-TB.